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IMMUNOLOGICAL ASPECTS OF DEOXYRIBONUCLEIC 
ACID AND CARCINOGENESIS 
INTRODUCTION 
Physiological functions of the reticuloendothelial system (RES) 
have been established in terms of lymphopoiesis and lymph node regen-
eration, tissue repair, phagocytosis and cellular and humoral immunity. 
The concept is generally accepted that immunity, resulting from the 
participation of the RES, is specific in the sense that each antigen 
stimulates the formation of antibody for itself and no other antigen. 
However, the response of the RES in neoplastic disease has more general 
and less precisely defined characteristics. Thus, the role of the 
RES and the part it plays in cancer immunity should be carefully con-
sidered. 
Attempts to apply immunologic theory and methods for a better 
understanding and treatment of cancer have been tried since Paul Ehrlich 
first worked in this field. Publications from clinical medical liter-
ature have indicated in Some instances that improvement in cancer 
patients has resulted from treatment with antisera and vaccines; how-
ever, on the basis of scientifically acceptable data that has been 
published there is still no definitive immunologic basis for the treat-
ment of neoplastic disease. 
Applying the principles of immunology purely upon theoretical 
grounds, the successful eradication of cancer appears to favor the 
prophylactic approach rather than the treatment of an established 
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neoplasm. Southham (1961) reviewed the application of immunology 
to cancer and considered the experimental approach from four different 
aspects. These were: 
1. "attempts to apply methods of specific immune therapy to 
the treatment of patients with advanced cancer; 
2. passive immunization for the treatment of cancer; 
3. stimulation of nonspecific host defense; 
4. prophylactic immunization against cancer." 
Southham concluded from this comprehensive survey that the first 
three statements have contributed little of practical significance 
in the treatment of cancer. 
Most of the major effort in immunologic approach has been con-, 
cerned with cancer therapy, even though the basic immunologic achieve-
ments have been with prophylactic immunity against disease. Transposing 
immunologic concepts to the prevention of cancer as with the prevention 
of bacterial disease would involve injection of the causative agent 
(neoplastic cells) into the host before the occurrence of disease 
or early in its course. Although the results of such efforts to date 
have not been promising in humans, this does not invalidate the approach. 
That is, in terms of immunologic theory one should consider the pros-
pects for cancer prevention by immunologic methods. This in itself 
is a formidable task, since it necessitates a search for specific 
antigens in neoplastic tissue. 
3 
Rapport and Graf (1961) considered "cancer-specific" antigen 
to mean a constituent found exclusively in cancer tissue and, there-
fore~ presumably "foreign" to the hosto The premise is that such a 
substance would provoke an antibody response in the host which would 
be detrimental to the tumor. The antigenic substance would possess 
two qualities or attributes; first, that the distinctive constituent 
be antigenic in the host; and, second, that the antibody evoke a 
reaction injurious to the tumor cells. 
An effort has been undertaken to more precisely define an antigen 
from cancer tissue. If such an antigen were available for immunization, 
competitive antigenic inhibition would be minimized and the concentration 
of antigen per unit volume injected could be increased. Since Avery 
~ al. (1944) found that deoxyribonucleic acid (DNA) was the agent 
of bacterial transformation, much interest has been centered around 
its biologic activity. Interest has increased since Watson and Crick 
(1953) made their famous proposals about the structure of DNA and its 
mode of self replication. Nucleoproteins (DNP) and DNA are of interest 
with respect to cancer because they are important constituents of the 
chromatin structure in the cell nucleus. Considering the morphologi-
cal irregularities in chromatin structure of the nucleus of benign 
and malignant tumors, there appears to be a definite sequence of 
nuclear abnormalities (KOSS and Durfee, 1961). This consistent histo-
logical finding of abnormal chromatin in the nucleus of malignant cells 
suggest the possibility that DNP or DNA may be chemically or sterically 
different and antigenically distinct from its normal counterpart. 
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To test th~ hypothesis that DNP and DNA are antigenic, and that 
these substances derived from cancerous cells might induce resistance 
to neoplastic disease, the following investigations were undertaken: 
(1) DNP and DNA were prepared from EAT and S37 ascites tumor cells. 
(2) The prepared material was used to immunize mice subsequently 
challenged with viable tumor cells. (3) Specificity of reaction was 
tested by challenge with an ascites tumor other than that used for 
immunization. 
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REVIEW OF LITERATURE 
It wasnft until the beginning of this century that scientists 
began to design experiments to fit a particular set of circumstances. 
Before this time they were content to make casual observations of what 
was either present or occurred spontaneously in nature. Admittedly 
many of the experimental tools were lacking,at this time but the 
scientific approach was also unimaginative by current standards. 
Emergence from this era to the present one came about slowly but as 
attitudes changed so did the lines of endeavor. 
Forerunner of experimental studies of carcinogenesis was the 
finding of Percival Pott (Stewart, 1959) who published a description 
in 1775 in "Chirurgical Observations" of a carcinoma of the skin, 
cancer scroti, occurring in chimney sweeps. His observations traced 
the causative agent to the soot to which the chimney sweeps were 
constantly being exposed. It wasn't until a century and a half later 
that Yamagiua and Ichikawa (1914) using coal tar were able to confirm 
that carcinogens did exist and the carcinoma of the skin could be 
induced in rabbits by repeated application to the skin for sufficient 
lengths of time. Since this first successful induction of tumor by 
a carcinogenic agent, many experimental models have been tried in 
efforts to obtain insight concerning the mechanism of this disease, 
its induction as well as its prevention. 
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Since many of the terms used in the literature in dealing with 
transplantable tumors are conflicting, it would be well to define 
certain terms pertaining to this investigation. 
Neoplasm as defined by Ewing (1940) is an uncontrolled new 
growth of tissue. The term "tumor" is applied to any neoplasm, benign 
or malignant. A cancer is a malignant neoplasm which eventually kills 
the host. Carcinoma is a malignant tumor of epithelial origin; sar-
coma is one which arises in mesenchymal tissue. A teratoma may be 
either benign or malignant and is reproduced from ectoderm, entodern 
and mesenchymal tissues. For the purpose of this investigation, 
carcinoma, tumor and cancer will be used synonymously. 
The term ascites tumor has come to denote a process in which, 
following inoculation of tumor cells into a body cavity, the tumor 
cells multiply, and there is effusion of fluid containing a suspension 
of neoplastic cell (Stewart et a1., 1959). 
Snell (1959) suggested the following terms in his discussion of 
transplantable tumors. 
An inbred strain of animals is one resulting from matings of 
brothers and sisters for 20 or more consecutive generations. Some 
increase in homozygosity occurs after the twentieth generation, but 
for most purposes inbreeding for 20 generations is adequate. An equi-
valent increase in homozygosity is produced by parent-offspring matings, 
provided that where consecutive parent~offspring matings are made the 
cross is always to the younger of the two parents. 
An autotransplant or autograft is one in which an individual is 
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grafted with its own tissue. 
An isotransp1ant or isograft {isogeneic graft) is one in which 
tissue from an individual of an inbred strain is grafted to another 
individual of the same inbred strain. 
A homotransplant (allograft or allogeneic transplant) is a trans-
plant between individuals of the same species but of different genotypes. 
Typically, it is a transplant from an individual of one inbre.d strain 
to an individual of a second inbred strain. 
A heterotransplant (xenograft or xenogeneic transplant) is a 
transplant between different species, as from rat to the mouse. 
More recently, based on Gorer's (1960, 1961) suggestions, 
Russel and Menaco (1964) tabulated a desirable terminology of tissue 
transplantation which is shown in modified form in Table I. 
An orthotopic graft is one which is placed in proper anatomic 
position, i.e., skin to skin, kidney to renal fossa with proper 
anastomosis at renal pedicle. 
A heterotopic graft is one which is in an unnatural position, 
eg., adrenal tissue in peritoneal cavity. 
It is apparent from Table I that Snell's suggested terminology 
should now be modified to replace the terms given in parentheses. 
Other conflicting terms among investigators involve description 
of the type of immunity elicited by different tumor host systems; 
these are: autoimmunity, isoimmunity (isogeneic immunity), and homo-
graft (allogeneic) immunity. These term$ are defined by Hirsch (1958) 
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TABLE I. 
Tissue Transplantation Vocabulary 





Older, Less Correct 






Donor of graft tissue 
is also recipient 
Grafts of tissue between 
inbred strains or "iden-
tical" twins 
Grafts of tissue between 
members of "wild" strains 
i.e., homologous members 
of species 
Grafts between species 
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as follows: autoinnnunity is "innnunity elicited in an animal against 
his own normal or tumor tissue." The host then is referred to as the 
autochthonous host. Isoinnnunity (isogeneic immunity) is defined as 
"immunity elicited in a ':imber of an inbred strain against normal 
or tumor tissue of another member of the same inbred strains"; and 
homograft (allogeneic) immunity is defined as "innnunity elicited in 
an individual against normal or tumor tissue of a genetically different 
individual of the same species, or that elicited in animals of one 
inbred strain against normal or tissue of members of other inbred 
strains of the same species." The terms given in parentheses are 
used hereafter. 
The concept that cellular antigens specific for cancer may 
exist ha~ been formulated by several investigations: Hauschka (1952) 
and more recently Southham (1960), Green (1961), Law (1961), Hirsch 
(1962), and McKhann (1965). Although, as these authors have indicated, 
greater insight into the mechanisms involved in cancer innnunity is 
constantly being achieved, it remains difficult to identify tumor 
specific antigen. 
Innnunological reactions that are attributable to antibody 
produced by the host against its own tumor should bear some relation 
to the presence of "foreignll constituents in cancer. An experimental 
design for detection of this circumstance is as follows: a cancer 
tissue homogenate or a subfraction is injected into the test animals 
and the animals are then either subjected to challenge by the original 
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tumor or standard immunologic procedures should be tried to demon-
strate an antibody to the test material. There is considerable 
evidence that injection of cell homogenates or subfractions is followed 
by formation of antibodies. Formation of antibodies directed against 
cellular antigens has been demonstrated by Gorer (1938, 1942, 1948) 
and Goldner et al. (1959). Harris ~ al. (1954) and Snell (1960) 
concluded from experiments involving immunization of mice with homo-
genates of thymus glands that cellular immunity is of lymphoid origin. 
Law (1961) in a review of immunologic aspects of carcinogenesis sug-
gested that in transplantation immunity the reaction is apparently 
provoked by nuclear antigens. 
Makari (1962) presented evidence that carcinoma antigens pos-
$essed a high degree of specificity. If such antigens are unique 
in cancer tissue, then there is clearly the possibility for prophy~ 
lactic immunization. If we are to accept the hypothesis that some 
constituents of cancer cells are antigenical1y different from their 
normal counterpart, then the need to search for specific antigen (s) 
in neoplastic tissue is evident. 
Landsteiner (1946) supported this conclusion with the following 
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statement: the experience of poor and wanting antigenicity of animal 
nuc1eoproteins which are composed of nucleic acids and his tones or 
protamines is intelligible since, as evidence hitherto existing would 
indicate, the protein components have no appreciable antigenic cap-
acity. Bacterial and virus nuc1eoproteins, on the other hand, were 
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. found to induce antibody production. In view of positive results 
with some nuc1eoproteins of animal origin it would be worthwhile 
to resume the subject with the use of well purified and unaltered 
It 
preparations. 
I. RES ISTANCE TO TUMOR TRANSFLANTS 
A. Antigenic Basis of Resistance to Transplants. 
Although the problems encountered in the investigations 
described in this thesis do not directly pertain to other well estab-
1ished concepts of the antigenic basis of resistance to tumor trans-
plants, no discussion of tumor transplantation would be complete 
without citing some of the concepts established by Gorer and his 
colleagues. Gorer (1938, 1942, 1948, 1962) has shown that isoanti-
bodies could be produced in certain tumor-host combinations in mice. 
Gorer's (1938) original concept of antibody formation was traced 
to specific gene differences between donor and host. Using inbred 
strain A and C57BL mice and employing a leukemia specific for the 
A strain animals, it was found that by challenging strain C57BL with 
leukemia cells of A strain that agglutinins for A strain erythrocytes 
developed. Since the agglutinins could be absorbed by the A strain 
tumor cells, it was concluded that strain A tumor cells and erythro-
cytes shared a common antigen. This antigen designated as antigen II 
could also be demonstrated by injecting A red cells into rabbits and 
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producing antiserum. This antiserum would specifically agglutinate 
A red cells when absorbed with C57BL red cells. 
Later experiments by Gorer and Amos (1956) showed that it was 
possible to obtain protection by passively immunizing C57BL mice 
with antiserum obtained by immunizing foreign strain mice with leukemia 
EL4. Absorption in vitro with normal C57BL liver failed to deplete 
the passive immunity. However, when the same antiserum was absorbed 
with EL4 cells, there was a marked reduction of protective activity. 
In order to establish the specificity of this antigen, foreign strain 
mice were immunized with normal tissues and mammary carcinoma of the 
C57BL, and these mice failed to provide any passive immunity as com· 
pared with antiserum prepared with EL4 cells. Gorer et al. (1962) 
tried to establish the identity of the antigen which they designated 
as X. Using a series of leukemic cells from different sources, three 
distinct X antigens were found. One of these antigens cross·reacted 
with the other two X antigens. They concluded that these antigens 
may be variations of normal elements found specifically in leukemic 
cells, or that th~y may represent marked quantitative antigenic 
differences between leukemic and normal cells of similar genetic 
origin. 
Kidd (1938, 1940a, 1940b) uSing antisera obtained from rabbits 
with Brown-Pearce tumor which had regressed, was able to demonstrate 
complement·fixation with tumor antigen. Although this finding fur-
ther substantiated Gorerrs work, the antigen did not appear to be 
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specific. Absorbing the antisera with both normal and with Brown-
Pearce tissue extracts, it was shown that two different antibodies 
were present: (1) an antibody that reacted with both normal tissue 
and tumor extracts; and (2) an antibody specific for tumor extracts. 
From these investigations it appears that tumor cells per ~ 
contain a specific substance or substances that are antigenica11y 
demonstrable. The results, although conflicting in Some instances, 
indicate that tumor cells do contain specific antigens and that they 
can e1icite an antibody response. This antibody can be demonstrated 
not only in vitro by agglutination and complement-fixation procedures 
but also in vivo by passive immunization. 
B. Enhancing Effect 
The main purpose of this investigation was to study means of 
increasing resistance to tumor cell implantation. However, in other 
circumstances it would be profitable to increase the survival of 
tumor tissue and without question one must find practical procedures 
to induce the survival of tissue grafts from donor to host. The 
rejection or acceptance of tissue whether it be normal or neoplastic 
is related basically to the total problem of transplantation. Super~ 
ficia11y both processes appear to be a opposite extremes; however, 
from an immunological basis, the processes must be intimately related 
to each other. 
Ka1iss (1958) defined immunologic enhancement as " ••• the success-
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ful establishment of a tumor homograft and its progressive growth 
(usually to death of the host) as a consequence of the tumor's con-
tact with specific antiserum in host. II The primary requisite for 
growth of a tumor that would be normally rejected is conditioning 
the host; this may be done either by active or passive immunization. 
Conditioning the host is carried out by pretreating animals with 
tissue, not necessarily from tumor tissue itself but tissue that 
must share certain genetic factors with the host's tissues. In 
other words, the effort is made to induce "tolerance." Kidney, 
liver, and spleen have been found to produce enhancement as well 
as the tumor itself (Kaliss and Snell, 1951). The pretreated animal 
will die from progressive tumor and the controls will reject the 
transplant and survive. This phenomenon therefore has been called 
"immunological enhancement" to distinguish it from other experimen-
tal conditions that may cause rejection or survival of the graft. 
Kaliss (1962, 1965) considering the mechanisms of enhancement 
found that more uniform results could be produced by passive rather 
than by active immunization. This is expected, as animals, even if 
inbred, vary in their response to immunologic stimuli. If active 
immunization is carried out, killed tissue is more effective for 
enhancement as it does not produce an efficient cellular response, 
but does induce a good humoral response. Live tissue produces a 
"second set" response and rejection rather than enhancement. Tis-
sues used for the enhancement effect generally have been killed by 
freeze'~drying in order to preventextens i vedenaturation. 
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The enhancement effect is highly specific. Kaliss and Newton 
(1949) have shown that non-mouse tissue does not produce enhancement 
of mouse tumor homograftse Snell~ ~ ale (1953~ 1954~ 1955) indi-
cated that in order for tissue cells to be effective in enhancement 
they must possess certain histocompatiblity genes, and that the 
isoantigens resulting from these genes must be common with the tumor. 
He designated these genes as H-l, H-2, and H-3, and believed them 
to determine the susceptibility and resistance to transplants. 
Kandutsch (1956) has presented evidence from chemical studies 
that the enhancing substance contains both mucopolysaccharides and 
protein. Experimentally, at least in some instances, this appears 
to be substantiated. Generally it is conceded by most investigators 
that the active antigenic portion of the ABO system are blood group 
substances composed of mucopolysaccharides. As previously stated 
in Gorer's original work, since there was a common antigen between 
leukemia cells and A cells, the antigens are mucopolysaccharides 
in nature. 
Although the exact mechanism of immunologic enhancement is still 
open to speculation, it is generally agreed that primarily the reaction 
is due to contact between graft and antigraft antibody. Kaliss (1962) 
has stated that various investigations have attributed the mechanism 
of enhancement to: (1) "afferent" blockage of the immune stimulus; 
(2) "central" blockage of the immune response; (3) "immunoselection" 
of insusceptible cells in a mixed antigenic population of tumor cells; 
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(4) on some alteration in the enhanced graft that makes the graft 
resistant to the host's immune response. It was Kaliss' belief 
that immunoselection has been ruled out and that there is some 
evidence against the blockage hypothesis. He supported this by 
stating that enhancement of Sarcoma I grafts in C57BL mice would 
be obtained by injecting "enhancing" antiserum one week after tumor 
inoculation, when the homograft rejection reaction is maximum. 
Whatever the mechanisms that contribute to immunologic enhance-
ment, it must be concluded from this review, that one can still only 
speculate concerning the reactions that are involved. It appears 
then, that an antigen-antibody reaction occurs and that specific 
antigen(s) exist. Whether this antigenic quality is due to gene 
differences expressed as specific substances within the cell or in 
some other manner remains unknown. We can only hypothesize that 
within the cell certain antigenic differences exist and that defini-
tion of this substance or substances await further experimentation. 
C. Increased Resistance. 
Immunology with all of its ramifications is still primarily 
concerned with augmenting resistance to disease. The goal of an 
immunization procedure is to prevent or ameliorate the course of 
disease whether it be bacterial, viral or neoplastic in nature. Of 
course, the greatest success in inducing increased resistance has been 
with bacterial and viral diseases, in which cases the antigenic com-
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ponents are more precisely defined. However with cancer, the anti-
genic components of the cell have less definition, and methods of 
testing for antibody response are not often revealed by classical 
immunological methods. One of the major purposes then of cancer 
investigation is to seek a "specific" antigen and to augment resis-
tance in the host. 
All investigations of malignancy to date have failed to reveal 
any antigenic qualitative distinction for the mobilization of defense 
mechanisms against this disease. Antigenic differences noted by 
workers in cancer immunology have yet to be resolved. However, on 
the basis of some experimental evidence the possibility exists that 
certain neoplastic tissues do possess antigens and that these anti-
gens are qualitatively distinct. Progress in cancer immunology has 
been reviewed by Woglom (1929, Hauschka (1952), Foley (1952), and 
more recently by Milgrom (1961) and Southham (1965). The studies 
cited in these reviews have served to emphasize the specificity of 
induced immunity to neoplastic disease. 
If we are to accept the hypothesis that some constituents of 
cancer cells are antigenically different from their normal counter-
part, we should first reconsider and evaluate some of the present-
day ideas. Southham (1961) stated that regardless of the fundamen-
tal efficacy of defense mechanisms against cancer, the patient who 
has acquired cancer must be an individual who has failed to respond 
to the stimulus of his own cancer. In effect this is certainly true, 
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but on the other hand, if we compare different states as exhibited 
in bacterial infectivity and immune response we could derive the 
same conclusions with regard to infective disease. 
There is considerable evidence that fragmented cells and 
extracts of tumor tissue used as antigens are accompanied by forma-
tion of antibodies. Marshak and Erf (1941) immunized a small percen-
tage of mice against lymphoma by first giving subcutaneous injectiOl~S 
of fragmented lymphoma cells and isolated lymphoma cell nuclei. 
Goldfeder (1945) immunized rats against lymphosarcoma using similar 
tumor tissue from irradiated rats. Aptekman et a1. (1946, 1949) 
also were able to immunize rats against transplanted and induced 
sarcomas; however, these investigators used alcoholic extracts of 
the tumors. 
Quantitative studies of Old ~ a1. (1961) indicated a wide range 
of antigenicity of induced tumors, from strongly antigenic to no demon-
strable antigenicity. Depression of the antibody forming system after 
carcinogenesis should increase tumor incidence, particularly with 
the common therapeutic procedures which depress antibody production. 
Furth (1963) has implied that when antigenic cancer cells attain 
such a mass as to constitute an antigenic excess, there is created 
an "immunologic paralysis," which inhibits effective circulating 
antibodies. It follows then that continued depression of immunologic 
capacity, during which the tumors attain a sizable mass, can create 
a fatal immunologic paralysis. 
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Recently several investigators have tried to search for the 
presence of antibody individuals in whom tumor arose. In the studies 
of Graham and Graham (1955) and Marcissov and Abelev (1959), antibody 
was detected in the patient's serum by the method of complement-fix-
ation. Makari (1962) demonstrated antibody in cancer patients by 
the Schultz-Dale technique, using sera from subjects with and without 
neoplastic disease. Grace and Kondo (1958) based their results on 
skin sensitivity to intradermal injection of a tumor extract and pas-
sive transfer using the patient's serum. Each of these studies indicate 
that antibody was found in only a limited number of cancer patients. 
For example, in the studies of Graham and Graham, tests were positive 
in only 12 out of 18 patients; in those of Makari 90.2% were positive 
in subjects with carcinoma and 25% positive in normal individuals; 
Grace and Kondo reported positive findings in only eight selected 
patients. In the study of the Grahams, it was shown that the "anti-
body" may be individual-specific, which makes it difficult for further 
study. Makari did not believe that 25% false positives distracted 
from his test, as it was an advantage as a screening procedure. 
Rapport and Graf (1961) concluded from their experience that 
some antigens may be too specific to be utilized for immunization, 
but genetically controlled antigens that make tissues "individual-
specific", i.e. nontransplantable, are also present in cancer tissue. 
Makari (1962) on the other hand presented evidence that carcinoma anti-
gens have a high degree of specificity. If such antigens are unique 
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in cancer tissue, there is clearly a possibility for prophylactic 
immunization. 
As indicated from the discussion on immunologic enchancement, 
there is no longer a question whether or not cells can proliferate 
in heterologous hosts if no immune forces come into play. A question 
that is foremost in tumor investigations is concerned with factors 
necessary for increasing resistance of the host against viable tumor 
cells. Generally speaking the use of killed cells as a vaccine has 
been found to be unsatisfactory. Most of the successful immunization 
procedures have been carried out using live cells or cells altered 
by x-irradiation. It could be hypothesized from this that methods 
used for killing tumor cells have destroyed their antigenic capabil-
ities and are no longer recognized by the host. From the work of 
Medawar (1954) it is apparent that the animal host reacts to differ-
ent homologous tissue as it does to bacteria and foreign proteins. 
Thus, the stability to preparatory treatment of the materials used 
in immunization would determine whether they still retained their 
antigenic qualities. 
Goldfeder (1945) and Donaldson and Mitchell (1959) have shown 
that x-irradiated tumor cells could induce resistance to later in-
jection of viable cells. However, Goldfeder (1942) demonstrated 
that sarcoma 180 cells conferred active immunity if the cells were 
irradiated in vitro with 4000 - 5000 rad but not 60,000 rad. Hill 
and Marcus (1960) and Baillif (1960, 1964) were able to increase 
resistance by injecting viable Ehrlich ascites tumor cells intraven-
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ous1y but failed to induce immunity by using cells killed by formalin. 
These reports indicate that the antigenic capabilities of cells are 
easily destroyed~ but that the use of live cells or cells but slightly 
altered by x-irradiation increased resistance to subsequent challenge. 
II. TRANSPLANTABLE TUMORS 
A. Induction. 
Since yamaguia and Ichikawa (1914) induced carcinoma for the 
first time in the skin of rabbits by painting with tar, many experi-
mental models f9r the study of carcinogenesis have been introduced. 
Neoplasms of many different types have been induced and transplanted 
tn a variety of animals. Snell (1959) has compiled a list of trans-
plantable neoplasms, which conveys some ide~ of the great variety 
of tumors and the number of different organs that are involved. The 
list includes spontaneous tumors and also tumors induced by chemical 
and physical means. Stewart, Snell, Dunham, and Sch1yen (1959) 
have also compiled a monograph describing transplantable and trans-
missible tumors of animals in detail. 
Since Foley (1953) first demonstrated that subcutaneous sar-
comas induced by 3-methy1cho1anthrene in one member of an inbred 
strain of mice were antigenic in isologous hosts, chemically induced 
tumors have gained considerable popularity in the study of the immun-
ology of tumorgenesis. This was later substantiated by Prehn and 
Main (1957) and Klein !! a1. (1960) who were able to induce a tumor-
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specific immune state in isologous mice or even in the autochthonous 
host. Prehn (1960) was also able to demonstrate similar results with 
another polycyclic hydrocarbon, dibenz~thracene. However, in physi-
cally induced tumors, such as tumors induced by implantation of milli-
pore filters, an immune mechanism is less well defined, (Prehn, 1961, 
1965). 
Recently extensive use of ascites tumors has been made in the 
study of tumorgenesis. This has been made possible by conversion 
of solid tumors to ascitic form (Klein, 1955) and New York Academy of 
Science conference on ascites tumors, Hauschka (ed.) (1956). The 
use of ascites tumors as compared to solid tumors has several advan-
tages: (1) cell counts and LD50 values can be readily ascertained; 
(2) death is rapid; (3) transfer and propagation of the tumor can be 
readily accomplished. The disadvantages of using this type of tumor 
are that the course of the disease resembles an overwhelming infection, 
the eXistince of immune mechanisms can generally be studied only by 
resistance to challenge, and in most cases the tumor is nonspecific 
in the sense that it will grow in any strain of mice. 
The use of solid tumors offers a better means to evaluate the 
immune response, particularly when using autochthonous hosts, since 
the tumor can generally be completely excised and then reinoculated 
as a challenge dose. The course of death, however, is markedly 
prolonged, individual cells in suspension are difficult to obtain, 
and LD50 values are therefore difficult to determine. The technical 
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difficulties in measuring the number of cells in the inoculum 
and the laborious task of mouse to mouse transfer by trocar imp1an-
tation of tumor cells are evident. 
The different routes of inoculation, size of inoculum and age 
of the tumor used have a profound effect on success of transfer of 
any experimental tumor. This appears to be true whether using an 
ascites or solid tumot:. Oshiro (1963) demonstrated a markedly dif-
ferent LDSO value using various routes of challenge with S·37 and 
EAT ascites tumor cells. Oshiro's results indicate, in the case 
of EAT cells, that one virulent tumor cell can induce lethal disease 
via the intraperitoneal route. In contrast to this highly "infectious" 
route, mice were found to tolerate an intravenous injection of 106 
tumor cells without evidence of mortality. The LDSO values of S·37 
tumor, via the subcutaneous and intravenous' routes were 1.25 x 105 
and 3.2 x 103 cells respectively. These findings vividly demonstra-
ted not only the different dose responses with the tumors used but 
also the significance of the route by which the challenge dose was 
administered. 
The number of cells as well as the age of the donor tumor that 
is transplanted is important to success of the transplant. Zah1 and 
Drasher (1947) found that seven-day growths of sarcoma 180 (Crocker 
tumor) contained mostly viable cells while two and twelve-day growths 
contained many necrotic cells. This observation was checked by 
measuring growth rates of the seven-day old tissues as compared to 
the two and twelve-day old tissues. 
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B. Transformation. 
Transformation is the change that occurs in transplantable 
tumors during repeated transfer. The changes that occur are not 
only in the direction of decreased host specificity and increasedl 
virulence but also morphologic changes of cell types. The tumor cells 
that an experimenter uses for a particular set of experiments may be 
different from those which were employed previously and from those 
employed at a later date. 
Miller and Taylor (1948) using a strain of A line leukemia cells, 
after many transfers, were able to decrease the time of death from 
fifteen to four d~~s. MacDowell (1946) was able to show in line 
M-liv leukemia cells an abrupt acceleration of growth during the 
seventeenth and eighteenth transfers. During these transfers the 
the time of deaths decreased gradually from 45 days to 5 days and 
then remained stable for many transplant generations. This suggested 
that a biologic adaptation occurred on the part of the tumor cells. 
Morphological changes have also been noted in tumors after 
many transfers. Stewart ~ al. (1947) noticed that in isogeneic 
transfers of pulmonary tumors in mice, a fibrosarcomatous trans-
formation occurred and that many of the tumors retained mixed carcin-
omatous and sarcomatous characteristics through a number of genera-
tions. A few of the tumors ultimately became pure sarcomas. Whether 
or not the observed changes were due to an unrecognized mixture to 
tumor cell types and were merely a case of selection is open to 
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speculation. However, Cooper !! ale (1944) noted that there was a 
loss of keratininzation after 20 subcutaneous passages of asquatnous: 
cell carcinoma. 
Variation of present day lines of tumors also becomes evident 
from the difference in nutritional requirements observed in tissue 
culture. Puck and Fisher (1956) have reported that with Hela cells, 
variants were produced that show different nutritional requirements. 
Furthermore, Sacks and Gallily (1955) studying the chromosomal 
number of ascites tumors, state that diploid tumors have a greater 
degree of strain specificity than do tumors characterized by more 
than a normal number of chromosomes. Stewart!! al. (1959) have 
reported a variation in the modal number of chromosomes from 45 to 
80 in EAT ascites tumor. Oshiro (1963) has described this same tumor 
as having a modal chromosome number of 60 with a range from 41 - 83. 
III. RETICULOENDOTHELIAL SYSTEM 
The reticuloendothelial system (RES) is composed in part of 
reticular cells, endothelial cells, fixed and wandering macrophages, 
and microphages of the blood. This system was first described by 
Aschoff (Bloom, 1962). The primary functions of the RES are to rid 
the body of worn out cells, foreign debris, and particles, animate 
or inanimate. Metchnikoff realized that although these cells were 
dissimilar under various physiological conditions, their protective 
function was the same. He called these cells macrophages and related 
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them to the defense mechanism in inflammation and immunity. Bloom 
(1962), thus, has termed the original RES, the macrophage system. 
A. Humoral Immunity. 
Despite the fact that a voluminous literature has accumulated 
concerning the role of humoral immunity in graft and tumor rejection, 
the subject remains controversial. Classical humoral antibodies to 
some experimentally induced tumor homografts are commonly produced; 
however, the participation of these antibodies in tumor rejection has 
been demonstrated only in a limited number of tumor-host combinations. 
Hericourt and Reichet (1895) were among the first to suggest that 
humoral antibody might be used in the treatment of an established 
neoplasm. Then, as now, host defense mechanisms to neoplasia were 
still to be delineated. 
The immune state may be acquired actively by introducing a 
foreign tissue into a suitable animal or it may be acquired passively 
by the introduction of antibody prepared in a homologous animal. 
Reactions of heterologous immune serum against homologous normal 
tissue or tumor grafts have been demonstrated by the cytotoxic 
activity of such antibody. Because this antibody is better demon-
started in allogeneic (homograft) or xenogeneic (heterograft) 
experiments, it has been used extensively in the search for tumor 
specific antigens. 
The cytotoxic activity of rabbit immune gamma globulin pre-
pared against Krebs ascites tumor has been shown by Green ~ al. (1959). 
27 
In ~ exposure of these cells to immune gamma globulin plus 
complement resulted in a loss of free amino acids, 30 - 60% cell 
protein and 90% of intracellular potassium. Ultrastructural studies 
by Goldb~rg and Green (1959) of the same system revealed a distinct 
alteration of the cellular membrane. When complement was subsequently 
added to the system, severe damage to the matrix, mitochondria, and 
endoplasmic reticulum was observed. 
Bjorklund et al. (1958) prepared antiserum in a horse by sub-
cutaneous injections of crude antigens from pooled human carcinomas 
over a period of several years. The rational for this immunization 
procedure was that an antigen mutually shared by cancers might even-
tually predominate over other antigens that are common to normal and 
cancer cells. Bjorklund and Bjorklund (1957) employed absoption 
methods and showed that the cytotoxic anticancer antibody was specifi-
cally directed towards a cancer specific antigen. These tests in-
volved a comparison of reactions between tumor or normal cell extracts 
and absorbed antibody. A method of assaying this antitumor antibody 
was described by Bjorklund ~t al, (1961). The assay involved the 
cytolysis of tumor cell cultures by the p~epared antiserum. 
Southham and Tetsuo (1963) were able to demonstrate isoanti-
bodies to human cancer cells in healthy recipients of cancer allo-
geneic (homo) transplants. Such transplants of nine cancer cell lines 
and two normal cell cultures were made in 20 healthy male volunteers. 
Sera collected before and after implantation were studied using the 
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tanned erythrocyte agglutination technique. The data demonstrated 
that the cancer cell lines contained an antigen or antigens in com-
mon which were foreign to the transplant recipients and were rarely 
detectable in the normal cell lines and normal tissues which were 
studied. These results are consistant with the concept that a humoral 
type of immunity can be demonstrated against cancer specific antigens. 
Old a1. (1963) were also able to demonstrate the cytotoxic 
effect of antiserum on tumor cells; however, the results of their 
investigations did not reveal a common antigen such as was shown 
in Bjork1unds' experiments. Viable cells from leukemic spleens 
induced by Friend virus in Swiss mice were injected into BABL/c mice 
to produce antisera. The cytotoxic activity of the antisera was 
restricted to leukemia induced by Friend virus but was inactive against 
three other mouse leukemias. 
Passive transfer of tumor immunity with sera has also been 
demonstrated. Lindeman (1964) demonstrated that serum or plasma 
taken from mice 3 to 8 weeks after viral oncolysis of EAT could 
transfer immunity to challenge by the original viable tumor. The 
technique used was to mix serum and tumor cells and to inoculate 
the mixture ip within one hour of preparation. Tyan and Cole (1963) 
were also able to demonstrate passive transfer of immunity. They 
presented data showing that the initial response to an allogeneic 
skin graft would be inhibited significantly in sublethally irradiated 
mice but that the response was essentially restored by passively 
transferred specific antisera. 
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B. Cellular Immunity. 
As previously mentioned there exists diversity of information 
and opinion concerning cellular reponse to tumor and normal tissue 
graft implantation. Recently Prehn (1965) has seriously questioned 
the role of humoral antibody and the part it plays, if any, in tumor 
immunology. Prehn believes that immunity as exhibited in neoplasms 
is' primarily a cellular phenomenon. However, many investigators 
ascribed to both humoral and cellular factors responsibility for 
acceptance or rejection of neoplastic implants. 
An immune type of reaction mediated by cells was first inden-
tified by Landsteiner and Chase (1942). They demonstrated that a 
delayed type of sensitivity to simple organic compounds could be 
transferred by cells and not by serum, Billingham ~ ale (1954a, 
1954b) have named this state of immunity "adoptive" immunity, that 
is, the immune state is transferred from one animal to another by 
immunologically activated cells. They showed that skin homografts 
on tolerant hosts would be activated immunologically after transfer. 
The skin homografts were accepted by the host, but could be subse-
quently rejected by intraperitoneal inoculation with lymph node 
fragments from mice of the allogenic strain. This concept of immune 
status mediated by cells has been further substantiated by Algire 
et ale (1955) who demonstrated that the reaction could be blocked 
by using membranes impermeable to cells placed intraperitoneally 
containing immunologically activated cells. 
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Baker et!!. (1962) concluded from their investigation of the 
immune destruction of Sarcoma I ascites tumor in the peritoneum of 
the C57 BL/LK mouse that such destruction was due largely, if not 
entirely, to the contact activities of the peritoneal macrophages. 
They stated that the findings which contribute most to this hypothesis 
are as follows: (1) among host cells of the ascites the macrophages 
were the only cells that showed a marked increase in concentration 
before the onset of tumor destruction; (2) the peritoneal macrophages 
were the only host cells that displayed mixed affinity for the tumor 
cells; (3) passive transfer of tumor immunity was accomplished with 
macrophage-rich ascites from actively i..nnnunized animals, but not with 
the sera, cel~-free ascites, and extracts of spleen and peritoneal 
cells from such animals; (4) when tumor cells were enclosed in cell-
impermeable millipore chambers and implanted in the peritoneal cavi-
ties of actively immunized animals, the cells remained viable for at 
least three weeks. Lindermann (1964) further supported this hypothe-
sis that cells from the immune host can confer tumor immunity with 
the following experiment: mice which had survived viral oncolysis 
and were challenged six weeks later with 106 EAT cells were killed 
five weeks after challenge. One group of normal mice received 
5 x 106 and another group 5 x 107 immune spleen cells/mouse intra ... 
peritoneally. After 24 hours the test and control groups were chal-
lenged with 104 EAT cells. All the control mice died, whereas all 
mice pretreated with cells survived. 
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This section may be summarized by stating that significant 
evidence exists to show that cells, both lymphocytes and macro-
phages, may be of prime importance in the rejection of certain 
tumors and allogenic skin grafts. 
IV. DEOXYRIBONUCLEIC ACID TUMOR ANTIGEN 
Early investigators of cancer immunity dealt mainly with 
attenuated cells, tissue homogenates and cell extracts. From the 
review that has been presented, it is apparent that the search for 
the elusive specific cancer antigen(s) still continues. These 
investigations, frequently yielding conflicting results, have a 
common purpose, that is the characterization of a cancer antigen and 
subsequent eradication of cancer through the use of immune procedures. 
'~upposing that a distinctive constituent has been detected in cancer 
tissue, how shall we proceed? We think the answer is straight for-
ward: find out what it is, determine its properties, then make it 
available for study in various experimental situations. These objec-
tives all require isolation of the constituent and we may therefore 
assign cancer antigens to different categories depending on the 
ease with which a given constituent may be isolated and identified" 
(Rapport and Graf, 1961). 
The discovery of nucleic acid was the result of work by 
Miescher (Jordon, 1960) who isolated in 1868 a substance that he 
called nuclein from pus cells. At this time he demonstrated the 
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highly polymeric character of nucleic acid, but unfortunately this 
was overlooked by later investigators. These workers using degrada-
tive methods of organic chemistry described the elementary constitu-
ents, but these analyses gave no hint concerning the structure of 
the biologically active molecule. 
It wasn't until Avery et ale (1944) found that deoxyribonucleic 
acid (DNA) was the agent of bacterial transformation, that it was 
considered biologically active. Some years later Hershey and Chase 
(1952) found that DNA is the main component that enters the host 
bacterium from an infecting bacteriophage. Shortly after this 
Watson a~d Crick (1953) made proposals about the structure of DNA 
and its mode of replication. Since then much progress has been 
made concerning the structure and biological behavior of DNA. 
With respect to cancer, nucleoproteins are of interest because 
they are the basic constituents of the chromatin structure of the 
cell nucleus. Considering the morphological irregularities in chromatin 
structure of the nucleus from the benign to malignant states, there 
appears to be a definite sequence of nuclear abnormalities. Histo-
logically these have been well described. Koss and Durfee (1961) 
have reviewed this problem and have established morphologically a so-
called "natural history of cancer." The series of events that lead 
to a carcinoma state, show nuclear abnormalities from hyperplasia, 
to metaplasia, to dysplasia and finally to the neoplastic product 
that fails to replicate itself as a functional cell. 
33 
Since the proposal by Watson and Crick (1953) concerning the 
~tructure of DNA, the trend of investigation has changed from mor-
phological observations of chromatin structure of the cell nucleus, 
to the chemical and biological effects of nucleic acids. The 
Watson-Crick model of the structure of DNA furnished a concept re-
garding the possibility of self duplication of this type of biologic 
polymer. Since their original concept was enunciated, many investi. 
gators have considered that the specific DNA molecules contained in 
their nucleic acid sequence the "information" required for the bio-
synthesis of protein. This suggests then, that nucleic acids act 
as "templates" for protein biosynthesis. This concept implies that 
if nucleic acids in malignant cells are chemically different, the 
replication of protein produced by these abnormal nucleic acids would 
be differen~ from their normal counterparts. 
Chemically speaking some methods of measuring pyrimidines 
and purines show little difference between tumor and nontumerous 
tissues, Miller ~ ale (1950a, 1950b), Bloom!! ale (1950). Wood-
house (1949) and Beal et ale (1950) reported considerable variation 
between the pyrimidines and purines in cancer tissue when compared 
to normal tissue. These differences reported between tissues appear 
to be based upon the analytical methods used and the means of degra-
dation of the nucleoproteins. 
Total content of nuclear DNA appears to vary with the type of 
tumor that is analyzed. Mark and Ris (1949) found that the DNA content 
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per nucleus of mouse hepatoma was similar to that of normal somatic 
cells. However, Klein et ale (1950) found a increased amount of DNA 
in Erhlich ascites tumor cells when compared with normal cells. Stich 
~ ale (1960) demonstrated the variability of DNA content between 
normal epithelium, polyps and adenocarcinomas of the large intestines 
of man. These investigations support the statement of Schmidt (1959), 
that the intricate problems of nucleoprotein metabolism are all prob-
lems of the "chemical anatomy" of nucleic acids. 
Evidence exists then to suggest that DNA from neoplastic cells 
in some instances appears to be different not only in amount, but also 
histologically and chemically when compared to normal cells. So far, 
in the utilization of DNA as an antigen, reports generally indicate 
poqr antibody response, Lackman etal. (1940) and Phillips ~ ale 
(1958). The data reported by these latter groups suggested that DNA, 
isolated from bacteria, may contribute to the antigenic specificity. 
Miescher ~ ale (1959) using DNA prepared from cells of salmon sperm 
and calf thymus demonstrated an antibody response in rabbits although 
it appeared very weak. It is assumed from these experiments that DNA 
showed a serological specificity but the antigenic qualities were 
poorly demonstrated. It appears likely that if the molecular integrity 
of the DNA molecule could be maintained upon extraction that the anti-
genic qualities might be enhanced. 
At present few reports are available concerning the possibility 
that DNA or DNP might be used to augment resistance to neoplastic 
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disease. Zi1ber (1958), because of his interest in the viral 
etiology of cancer presumed that nonfilterable tumors might still 
contain masked virus associated with nuc1eoproteins of the tumor. 
He isolated crude nuc1eoproteins from human and mouse tumors and 
instead of demonstrating oncogenic masked virus, found that the 
tumor nuc1eoproteins contained cancer-distinctive antigens. These 
antigens were demonstrated by immunizing guinea pigs and anaphylac-
tic response was used as a measure of antigenicity. Recently Perez-
Cuadrado ~ a1. (1964a, 1964b) further substantiated the production 
of specific antiserum to human cancerous tissue by immunizing animals 
with cancer cell particles containing DNA-bound protein. 
From previous data collected, Perez-Cuadrado ~ a1. (1965a) 
tried to characterize cancerous tissue antigens by immunohistochemical 
and ultrastructural methods. Treating cancerous tissue with ultra-
sonic waves and by differential centrifugation, they separated the 
cellular components into 10 fractions. Each fraction was subsequently 
used for immunization of rabbits. Immunization of these animals led 
to the production of several antibodies, some of which were specific 
for human cancer antigens. The antibodies were demonstrated by agglu-
tination of sensitized polystyrene latex particles. They found that 
the human cancer-specific antibodies were increased by immunizing 
antigens, which contained DNA-bound proteins from cancer cell nuclei. 
They further substantiated their findings (Perez-Cuadrado et a1., 
1965b), by testing the antibody produced by DNA-bound protein from 
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from cancerous tissue, using fluorescent antibody and agar gel 
double diffussion precipitation tests. From the evidence presented 
by these investigators, it is suggested that an immune response to 
neoplastic disease might be elicited by using unaltered DNA or DNP 
prepared from tumor tissue. 
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MATERIALS AND METHODS 
I. TUMORS 
A. Ehrlich Ascites Tumor (EAT), Ascites Form. 
The Ehrlich ascites tumor has been described by Stewart et al. 
(1959) as "an undifferentiated tumor that originated spontaneously 
as a carcinoma of the mammary gland of a stock mouse." The tumor was 
originally obtained by Ehrlich in 1907 and has been carried through 
mouse to mouse passage for an unknown number of transfers. The 
strain of EAT used in the proceeding experiments was obtained from 
the Sloan-Kettering Institute and is one of several strains of EAT 
used in cancer research. Variation in the present day line is un-
doubtedly different from the original tumor and appears to vary not 
only in nutritional requirements, as observed in tissue culture, but 
also under different environmental circumStances of mouse passage. 
Stewart ~ al. (1959) have reported a variation in the number of 
chromosomes from 45-80. The tumor used in this laboratory has a modal 
chromosome number of 60, with a range from 41-83 (Oshiro, 1963). 
Furthermore, as described later in the section on experimental results, 
the LD50 of this tumor in Oshiro's experiments was different from 
the LDSO described in this report, although the tumor was obtained 
from the same stock. 
B. Sarcoma 37 (S-37), Ascites Form. 
Stewart .!:! al. (1959) described this tumor as " a rapidly 
growing undifferentiated tumor that originated as a carcinoma of 
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the mammary gland of an untreated mouse." The tumor has been car-
ried by mouse to mouse passage since 1906 and is not specific for 
any strain of mice. In many respects it is similar to EAT except 
for the LD50 which will be described later. The strain of S-37 tumor 
used in this laboratory was obtained from the National Institutes of 
Health and has been carried in this laboratory for seven years. Both 
S-37 and EAT were maintained in this laboratory by weekly transplants 
of 0.25 ml of ascites into albino mice. 
II. ANIMALS 
Albino mice (Mus musculus) of mixed sexes were used in all 
experiments. Before each experiment mice were picked at random and 
caged in 7" x 13" plastic cages in groups of 12 or less. They were 
acclimated for three days before each experiment. The animals were 
given a diet of commercially prepared food and water ad libitum. 
III. TUMOR CELLS 
Free tumor cells were obtained by withdrawing peritoneal 
exudate from tumor infected mice into heparinized physiologic saline 
(PSS) solution. The tumor cells were separated from the serosanguin-
eous ascites fluid by centrifugation at 500 rmp for five minutes and 
decanting the supernatant fluid and red blood cells. The cells were 
"washed" three times in PSS, which resulted in a tumor cell suspen-
sion comparatively free from other cells. 
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Ehrlich and S-37 tumor cells were suspended in PSS and viable 
cells were counted in the hemocytometer by using a 0.05% solution 
of eosin in PSS as diluent. The unstained cells were considered 
viable. The cells were then diluted in PSS to the desired number. 
All injections were given in 1.0 m1 amounts. 
IV. PREPARATION OF DNP AND DNA 
DNP and DNA were prepared employing modifications of the several 
methods reviewed by Jordan (1960). Sterile procedures were employed 
throughout and in order to inhibit enzymatic degradation of DNP and 
DNA, all procedures were carried out at 4oc. unless otherwise indicated. 
A. DNP. 
Thirty gram portions of the sedimented ascites tumor cells were 
washed three times in 0.9% NaC1 and then blended in a high speed 
mixer for two minutes, with the addition of 20 m1 of 1% NaC1, pre-
viously adjusted to pH7 by the addition of sodium bicarbonate solution. 
The sediment collected by centrifugation was again resuspended in 
1% NaC1, mixed, and again centrifuged. To the sediment were added 
50 m1 of 10% NaC1, at pH7 and the suspension blended in the mixer 
for 15 seconds. The resulting viscous solution was then left standing 
and periodically stirred for one hour. The solution was poured into 
300 m1 of di$ti11ed water constantly agitated with a glass stirring 
rod and the resulting DNP precipitated into long viscous threads. 
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The DNP was collected by centrifugation and washed twice with 
distilled water. One gram portions of DNP were suspended in 6 m1 
of 0.9% NaC1 with the addition of 5 units of penicillin and 10 micro~ 
grams of streptomycin to insure bacteriostasis. The material was 
then stored frozen at -20oe. until ready for use. Protein analysis 
of DNP prepared from different tumors in this laboratory yielded 
approximately 2.4 grams % protein, using the Biuret method for 
total protein (Henery, 1964). 
B. DNA. 
DNA was prepared by digestion of protein from DNP with trypsin. 
One hundred mg of crystalline trypsin (Miles Chemical Co., Clifton, 
New Jersey) was added to 6 gms of prepared DNP' at Ph 7.4 and incu-
bated at 37oC. for 30 minutes. With addition of 70% ethyl alcohol 
the digested material was allowed to sediment in the refrigerator 
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at 4 C. The precipitate was washed twice in cold 70% ethyl alcohol 
and then 1 g~ portions were dissolved in 6 m1 of distilled water 
with the addition of 5 units of penicillin and 10 micrograms of 
streptomycin/m1 to insure bacteriostasis. The material was stored 
frozen at -20oC. until used. Protein analysis from different DNA 
preparations in this laboratory yielded values of less than 1 mg% 
of protein using the Biuret method for total protein determination 
(Henery, 1964). 
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c. DNP F~om Normal Tissues. 
Liver, heart, lung and kidneys were removed from mice and 
DNP prepared in the same manner as described for tumor cells. 
V. IMMUNIZATION 
Mice were injected intraperitoneally with 25 mg of DNP. Four 
injections were given with an interval of seven days between each 
injection. A similar immunization schedule was carried out using 
DNA, except the amount of inoculum was 10 mg. After the last in-
jection, there was a thirty-day interval before challenge. 
VI. PERITONEAL WASHINGS 
Peritoneal washings for microscopic observation of immune 
response were made at various time intervals. Mice were sacrificed 
and the peritoneal cavity washed with PSS. The collected fluid was 
centrifuged and wet and fixed smears made from the sedimented cells. 
VII. STAINING METHODS 
Two different stains were used for examination of cells; a 
supravital stain for the differentiation of histiocytes and leuco-
cytes from neoplastic and mesothelial cells in the ascites fluid 
and a modified Papanicolaou's stain for fixed cells. 
A. Papanicolaou Stain and Procedure. (Koss and Durfee, 1961) 
1. Wet smears on glass slides were fixed in 95% ethyl alcohol 
and ether, 1:1 for 20 minutes. The slides were then 
treated in staining jars as follows: 
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2. BO% ethyl alcohol - 10 dips 
3. 70% ethyl alcohol 
-
10 dips 
4. 50% ethyl alcohol - 10 dips 
5. Water - 10 dips 
6. Harris hemotoxylin - 2~ minutes 
7. 1% hydrochloric acid in 70% ethyl alcohol - 5 dips 
B. Running tap water - 5 minutes 
9. 50% ethyl alcohol - 10 dips 
10. 70% ethyl alcohol - 10 dips 
11. BO% ethyl alcohol 
-
10 dips 
12. 95% ethyl alcohol - 10 dips 
13. Orange G (stain) 
- l~ minutes 
14. 95% ethyl alcohol 
- 10 dips 
15. 95% ethyl alcohol 
-
10 dips 
16. EA 50 (stain) - l~ minutes 
17. 95% ethyl alcohol - 10 dips 
lB. 95% ethyl alcohol - 10 dips 
19. 95% ethyl alcohol - 10 dips 






22. Slide preserved with Permount and cover slip 
B. Supravital Staining (Koss and Durfee, 1961). 
Saturated solutions of neutral red and Janus green in absolute 
ethyl alcohol were prepared in separate well stoppered bottles. 
Dilute solutions were then made from each of these by adding 20 to 
50 drops of neutral red stock solution or 15 to 30 drops of the 
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saturated solution of Janus green to 10 m1 of absolute alcohol. 
For use, 10 - 50 drops of the dilute Janus green solution were 
added to 2 m1 of the dilute neutral red. A drop or two of this 
mixture was placed on a clean slide, another slide inverted over 
this wet stain and the two slides drawn apart so that an evenly 
distributed film was left on one side of either slide. For use, 
cellular material was smeared on the dry film of the stain. Janus 
green stains the lymphocytes and neutral red stains the granules 
of the histiocytes and also the polymorphonuclear 1eucocytes. Neo-
plastic or mesothelial cells, with few exceptions, did not stain 
by this method. 
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EXPERIMENTAL RESULTS 
I. 1Qso DETERMINATION 
It has been shown that greater accuracy in measuring immune 
response, and better economy in the use of animals can be exercised, 
if a dose can be determined which will kill SO% of the animals under 
test. This dose is better known as the LDSO (lethal doseSO)' If 
this value can be determined using variable numbers of viable tumor 
cells, then gradations of numbers of cells used for challenge in an 
immunized animal would be more meaningful. This value would also 
tend to establish a base line of reference for the study of degrees 
of resistance to tumor cell challenge. The hypothesis is set forth 
that a critical number of tumor cells might cause disease, while a 
lesser nu~ber would fail to induce tumor in the average animal. 
In order to test this hypothesis, known numbers of tumor cells 
were injected intraperitoneally into albino mice using strain-non-
specific ascites tumors. The tumors employed throughout this study 
were EAT and S-37 mouse tumor cells. Although these two tumors were 
indistinguishable morphologically, there was a striking difference 
in the number of cells needed for infectivity. The results shown in 
Tables 1 and 2 and Figures 1 and 2 indicate that the LDSO for EAT 
was approximately 103 cells, while that of S-37 was S x 104 cells. 
Not apparent from these tables is that the cause of death in animals 
challenged with both tumors appeared to be increasing ascites as 
histological sections showed no metastases to other organs. 
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Table 1. Mortality ratios following challenge with Ehrlich 
ascites tumor cells by the intrape~itoneal route 
with LD50 value* 
Challenge Dose Mortality % Mortality 
101 0/20 0% 
102 3/21 14% 
103 7/22 31% 
104 15/23 65% 
105 22/22 100% 
Numerical LD50 and 95% confidence limits 2,000 ± 560 
* Data analyzed by the method of Miller and Taintor (1944) 
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Figure 1. Probit tr~nsformation of mortality data following 
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Table II. Mortality ratios following challenge with 8-37 tumor 
by intraperitoneal route. LD50 value. 
Challenge Dose Mortality % Mortality 
101 0/23 0% 
102 0/22 0% 
103 0/22 0% 
104 3/23 13% 
3xl04 8/24 33% 
5xl04 10/23 43% 
5 
15/22 70% lxlO 
2xl05 20/23 87% 
4xl05 100/100 100% 
Numerical LD50 and 95% confidence limits = 45,000 ! 11,866 
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Figure II. Probit transformation of mortality data following 
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II. ABSOR~TION SPECTRUM OF DNA 
---, 
Purity of the prepared DNA from EAT and S-37 tumor cells 
WaS compared with a known purified standard of DNA (Sigma Chemical 
Co., St. LouiS, Mo.). The instrument used was the Beckman D U 
spectrophotometer. The ultraviolet absorption curves of the pre-
pared and standard DNA in distilled water were compared with each 
other. The resultant curves, as shown in Figure III. indicated a 
high degree of purity of the prepared material. 
III. IMMUNOLOGICAL RESPONSE TO DNP AND DNA 
-------
The hypothesis has been formulated that "cancer specific" 
antigens do exist and that these antigens can induce an immune 
response. The operational approach suggested was that by using 
essentially unaltered preparations, (Jordon, 1960) the prepared 
material would retain its antigenic identity. If this premise 
is true, then the antigenic capabilities of DNA or DNP would be 
increased and competitive antigenic inhibition, which is induced 
by whole cell homogenates, would be minimized. In order to test 
this hypothesis the following experiments were performed. 
In the routine transfer of EAT cells in control animals, death 
regularly occurred in one-half of the animals inoculated when approx-
imately 103 EAT cells were injected intraperitonea1ly. In order 
to evaluate the response in immunized animals over a wider range, 
challenge of 102 , 103 , 104 and 105 cells/animal were performed. 
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Similarly S-37 cells have an LDSO of approximately SO,OOO cells 
and immune response was evaluated over a range of Sxl04 , lOS, 
2xl05 and 4xl05 viable cells. Groups of 24 mice were employed 
for each dose. Each experiment was terminated after SO days, and 
the per cent living was compared to the per cent dead. A summation 
of the experimental design is shown in Figure IV. 
Table 111- shows the results obtained when mice immunized with 
DNP from EAT cells were compared to control animals; animals in 
both groups were challenged with varying numbers of viable EAT 
cells. Similarly, Table.tV summarizes results obtained with mice 
immunized with DNP from 8-37 cells and the control group; both groups 
were challenged with varying numbers of viable S-37 cells. The 
results supported the working hypothesis that a dose-response 
effect is apparent with both normal and immunized groups. Table III 
shows that in one instance 86% of the immunized animals survived as 
compared to 100% mortality in the control animals. Although the de-
gree of immunity was not as great in the 8-37 e~periment, nevertheless, 
SO% of the animals were protected as compared to 96% mortality in 
the control animals with a challenge dose of 4xlOS viable tumor cells. 
To test for the e~istance of cross immunity between DNP from 
EAT cells and 8-37 cells, mice were immunized with DNP of one tumor 
and challenged with cells of the other. The results are shown in 
Tables V and VI... The results demonstrated that mice immunized 




























Figure III. Absorption Spectrum of DNA 
Standard (DNA) ----
EAT (DNA) - - - -















Figure IV. 8ummation of Experimental Design 
Mice Immunized with Mice Challenged with 
DNP from EAT EAT cells 
DNP from 8-37 8-37 cells 
DNP from EAT 8-37 cells 
PNP from 8-37 EAT cells 
DNA from EAT EAT cells 
DNA from 8-37 8-37 cells 
DNA from EAT 8-37 cells 
DNA from S ... 37 EAT cells 
ON~ from normal tissu~ 8-37 cells 
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!able III. Comparison between mice immunized with DNP from EAT 
Gells ~nd the cpntrol group (saline treated) challenged 
with varying numbers of viable EAT cells. 






Mortality Mortality Value* 
0/20 0% 0/23 0% 
0/21 0'0 5/24 13% .10 
0/21 0% 16/24 67% (.001 
3/22 14% 22/22 100% (.001 
*Chi square analyeis with Yates' correction. Significant 
difference values underlined. 
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Table IV. Comparison between mice immunized with DNP from S-37 
cells and the control group (saline treated) challenged 
with varying numbers of viable S--37 cells. 
Challenge Immunized Per Cent Control Per Cent P 
Dose Mortality Mortality Value* 
5xlO4 6/22 27% 10/23 43% .5 -
lxl05 5/23 22% 13/23 56% .05 -
2xl05 7/23 30% 22/24 87% (.QQ!. 
4xl05 11/22 50% 23/24 96% 
*Cmi square analysis with Yates' correction. Significant 





Table V. Comparison between mice immuni~ed with DNP from EAT 
cells and the control group (saline treated) challenged 
with a varying number of viable S-37 cells. 
Challenge Immunized Per Cent Control Per Cent P 
Dose Mortality Mortality Value* 
5~104 4/21 19% 10/23 43% .2 -
lxl05 6/22 27% 15/24 62% .05 -
2xl05 7/21 33% 20/24 83% 
4xl05 11/23 48% 24/24 100% 
*Chi square analysis with Yates' correction. Significant 






Table VI. Comparison between mice immunized with DNP from S-37 
cells and the control groups (saline treated) challenged 
with a varying number of viable EAT cells. 
Challenge Immunized Per Cent Control Per Cent 
Dose Mortality Mortality 
102 0/22 0% 0/23 0% 
103 0/23 0% 5/24 13% 
104 5/23 21% 16/24 67% 
105 10/24 47% 24/24 100% 
*Chi square analysis with Yates' correction. Significant 







Table VII. C9mparison between mice immunized with DNA from EAT 
ce~ls and the control group (saline treated) challenged 
with varying number of viable EAT cells. 
Challenge Immunized Per Cent Control Per Cent P 
Dose Mortality Mortality Value* 
2 
10 0/16 0% 2/20 10% .2 
103 0/16 0% 9/20 45% .01 
104 0/16 0% 15/20 75% (.001 
105 6/16 37% 20/20 100% 
*Chi square analysis with Yates' correction. Significant 
difference values underlined. 
(.001 
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to the same extent as when DNP from 8-37 cells was used as the 
immunizer. However, when mice immunized with DNP from 8-37 were 
challenged with EAT cells, a lesser degree of protection was demon-
strated as compared to immunization with DNP from EAT. The results 
do indicate that although protection was diminished in this latter 
instance that a cross immunity between these two tumors did exist. 
8ince immunity as expressed in the foregoing experiments was 
greater than anticipated, it was desirable to determine if the pro-
t~in moiety of the DNP was necessary for immunogenicity. Protein was 
removed from the DNP as described in the Materials and Methods section. 
The results shown in tables VII and VIII support the premise that 
purified DNA retained its antigenicity even though protection was 
diminished as compared to DNP. This was particularly evident with 
mice immunized with 8-37 DNA. However, as was demonstrated in the 
previous experiment 8-37 DNP did not afford as high protection level 
against challenge with that tumor as did the EAT preparations against 
the EAT tumor. 
In order to test if the protein moiety of DNA may in Some way 
contribute to cross immunity of EAT and 8-37 tumors, purified DNA from 
EAT cells and 8-37 cells were used to immunize mice. The immunized 
mice were then challenged with 8-37 or EAT cells. The results shown 
in Tables IX and X indicate that cross immunity would still be demon-
strated, however, to a considerably lesser degree. 
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Table VIII. Comparison between mice immunized with DNA from S-37 
cells and the control group (saline treated) challenged 
with varying number of viable S-37 cells. 
Challenge Immunized Per Cent Control Per Cent 
Dose Mortality Mortality 
5xl04 8/20 40% 11/20 55% 
lxl05 11/20 55% 15/20 75% 
5 
2xlO 18/20 90% 20/20 100% 
4xl05 16/20 80% 20/20 100% 
*Chi square analysis with Yates' correction. Significant 




.5 - .3 
.5 - .3 
.2 
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Table IX. Comparison between mice immunized with DNA from EAT 
cells and the control group (saline treated) challenged 
with varying number of viable S-37 cells. 
Challenge Immunized Per Cent Control Per Cent P 
Mortality Mortality Value* 
5xl04 5/20 25% 11/20 55% . 1 
lxl05 5/19 26% 15/20 75% .01 
2xl05 11/18 61% 20/20 100% .01 
4xl05 18/20 90% 20/20 100% .5 
*Chi square analysis with Yates' correction. Significant 
difference values underlined. 
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Table X. Comparison between mice immunized with DNA from 5-37 
cells and the control group (saline treated) challenged 
with varying number of viable S-37 cells. 
Challenge Immunized Per Cent Control Per Cent P 
Dose Mortality Mortality Value* 
2 
10 0/19 0% 2/20 10% 
103 2/19 10% 9/20 45% 
104 1/20 5% 15/20 75% 
105 14/20 70% 20/20 100% 
*Chi square analysis with Yates' correction. Significant 
difference values underlined. 
.5 - .3 
.05 - .02 
.001 
.05 - .02 
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IV. IMMUNOLOGICAL RESPONSE TO ~ PREPARED ~ NORMAL TISSUE 
It has previously been stated that tumor cells are not only 
morphologically different (Koss and Durfee, 1961) but also chemi-
cally different (Mark and Ris, 1949 and Beal et al., 1950) from 
normal cells. Thus, if cancer distinctive antigens exist, they 
would not normally be demonstrated in non-cancerous cells. To test 
if an \mmune response might be elicited by DNP from normal cells, 
mice were immunized with DNP prepared from normal mouse tissue 
and subsequently challenged with EAT and S-37 cells. The results 
shown in Tables XI: and XII. supported the original hypothesis, 
i.e., immunological response to injection of DNP from normal 
tissue cells was not protective against challenge by either S-37 
or EAT. 
V. OBSERVATION OF IMMUNE RESPONSE 
In order to visualize microscopically the immune response, 
24 mice immunized with DNP from S-37 were challenged intraperitoneally 
with 4xl05 viable S-37 cells. At various time intervals the peri-
toneum was washed with 1 ml of PSS, and the cells were collected for 
microscopic study. A wet mount and permanent preparations were made 
with material from each animal in both the immunized and control 
groups. Two animals from each group were sacrificed at the given 
time intervals. The observations are listed in chronological order. 
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Table XI. Compairson between mice immunized with DNP from normal 
mouse tissue and the control group (saline treated) 
challenged with a varying number of viable EAT cells. 






Mortality Mortality Value* 
0/11 0% 1/12 8% ) .99 
4/11 34% 5/12 41% ) .80 
8/12 66% 7/11 63% } .90 
11/11 100% 10/10 100% 
*Chi square analysis with Yates' correction. Significant 
difference values underlined. 
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Table XII. Comparison between mice immunized with DNP and normal 
mouse tissue and the control group (saline treated) 
challenged with a varying number of viable S-37 cells. 
Challenge Immunized Per Cent Control Per Cent 
Dose Mortality Mortality 
5xl04 6/12 50% 5/12 41% 
lxl05 6/11 54% 7/11 63% 
2xl05 9/10 90% 10/12 83% 
4xl05 11/12 91% 11/11 100% 
*Chi square analysis with Yates' correction. Significant 








In order for the three different types of cells, tumor, lympho-
cytes and histiocytes to be distinguished, an enlargement was made, 
as is shown in Figure V, in order to classify the cells in the 
following photomicrographs. 
One Hour Sampling. 
Figure VI. Immunized. rhere appeared to be gross aggregates 
of tumor cells showing degeneration and a marked infil-
tration of lymphocytes and histiocytes. 
Figure VII. Control. Tumor cells appeared uniformly dispersed 
and very few lymphocytes and histiocytes were noted. 
Two Hour Sampling. 
Figure VIII. Immunized. Relatively few tumor cells were ob-
served but a marked lymphocytic and histiocytic response 
was still present. 
Figure IX. Control. Tumor cells were moderate in number and 
few lymphocytes or histiocytes were seen. 
Eighteen Hour Sampling. 
Figure X. Immunized. There appeared to be only a few tumor 
cells with a marked lymphocytic and histiocytic response. 
Figure XI. Control. Marked numbers of tumor cells, appearing 
as sheets and aggregates were noted. Within the aggre-
gated tumor cells some appeared which seemed to be histio-
cytes, otherwise the histiocytic response was slight. 
66 
TWENTY -!Q!!! !!.Q.!!! SAMPLING. 
Figure XII. Immunized. Only a few scattered tumor cells were 
seen with rare clumps of cells that appeared to be lysing. 
The histiocytes and lymphocytes were still abundantly 
present. 
Figure XIII. Control. Marked numbers of tumor cells and aggre-
gates were observed with a diffuse, marked increase in 
lymphocytes and some histiocytes. 
FORTY.,.EIGHT HOUR SAMPLING. 
Figure XIV. Immunized. Only a rare tumor cell was noted among 
many lymphocytes an9 histiocytes. 
Figure XV. Control. Massive numbers of tumor cells with many 
lymphocytes and histiocyte$ were observed. 
SEVENTY-~ HOUR SAMPL~NG. 
Figure XVI. Immunized. Only a rare degenerating tumor cell 
was observed among many lymphocytes and histiocytes. 
Figure XVII. Control. Massive numbers of tumor cells with 
few lymphocytes and histiocytes were observed. 
These results support the hypothesis of Baker et ale (1962), and 
--
Bennett (1965) that immune destruction of ascites tumor cells is due 
largely to the contact between peritoneal inflammatory cells, histio-
cyte$, and lymphocytes and tumor cells. If should be noted that the 
immune animals exhibited an immediate increase of cellular elements, 
while the control animals showed a 24-hour delay before histiocytes 
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and lymphocytes became prominent. Furthermore, there was a steady 
decrease in the numbers of tumor cells in the immune animal while 
the unimmunized animals showed a marked and overwhelming number of 
tumor cells after 24 hours. It is interesting to note that only 
after many tumor cells were observed in the control animals were 
histiocytes observed in any number. 
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figure V. Enlargement of the three types of cells that are shown in 
the following photomicrographs. Tumor cell (A), lympho-
cyte (B) and histiocyte (C). 
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ONE !!.Q.:Q! SAMPLING 
Immune 
(XIOO) 
Figure VI. Aggregates of tumor cells (A) and marked infiltration 
of lymphocytes (B) and histiocytes (C). 
Control 
(XIOO) 
Figure VII. Tumor cells (A) uniformly dispersed; few lymphocytes (B) 
and histiocytes (C). 
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TWO !!Q!I!! SAMPLING 
Immun~ 
(XIOO) 
Figure VIII. Relatively few tumor cells (A); marked lymphocytic (B) 
and histiocytic (C) response. 
Control 
(XIOO) 
Figure IX. Tumor cells (A) are moderate in number; few lymphocytes (B) 
or histiocytes (C) are seen. 
\: 
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Tumor cells (A) rare among many lymphocytes (B) and 
histiocytes (C). 
Massive numbers of tumor cells (A) with many lymphocytes (B) 
and histiocytes (C) present. 




Figure XVI. Only rare, degenerating tumor cells (A) observed among 
many lymphocytes (B) and histiocytes (C). 
Control 
(XIOO) 
Figure XVII. Massive numbers of tumor cells (A) with few lymphocytes (B) 
and histiocytes (C) present. 
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DISCUSSION 
The work that has been presented has involved the search for 
and characterization of a tumor specific antigen. The antigens DNP 
and DNA from tumor cells were employed to test the hypothesis that 
these antigens, so defined, could be used to augment resistant to 
neoplastic disease. Several conclusions can be made from the experi-
mental results. These are: the establishment of an LDSO and the 
standard error of this value, in terms of cell numbers for experi-
mentally transmitted neoplasms; that cancer specific antigens can 
be prepared from tumor cells, and there is enhancement of the immune 
response to cancer by the use of these antigens; there exists a cel-
lular and probably a humoral resistance mechanism. 
The LDSO values of EAT and S-37 tumor cells was noticeably 
different, even though the tumor cells are morphologically similar 
to each other. This implied that cells derived from EAT better 
resisted the influence of natural r~stance mechanisms as they 
existed. However, once the tumor process was established, the 
outcome of the disease always ended in death of the animal. It was 
established, at least through the course of these experiments, that 
the LDSO values remained stable. Any descrepancies varied within 
the standard error. Although the tumors used were derived from the 
same stock as Oshiro's (1963), who established infectivity with EAT 
as less than 10 cells, in the work reported in this thesis, LDSO 
values of greater than 1,000 cells were consistently obtained. The 
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basis for the difference in LDSO values in these two reports are 
purely speculative. The difference in LDSO values may be accounted 
for in the time factor between processing these cells to the desired 
concentration and injection time, which might affect the viability 
of the cells. Another possibility might be that the diluent used 
for cells in these experiments was PSS rather than Hanks balanced 
salt solution as in Oshiro's experiments. This might also affect 
the viability of the cells. 
The LDSO of S-37 tumor appeared to be more consistant with 
Oshiro's (1963) results. He reported an LDSO value of 2S,000 ± 
8,928. The results collected in this work and given in Table II 
were within that limit. 
The immune mechanisms that are operative in the establishment 
of an LDSO value for these models were not investigated. However, 
it may be deduced that since a dose-response effect existed and an 
LDSO value may be determined, some type of resistance must exist 
normally. That is, a normal resistance mechanism exists for this 
model of a mammalian neoplastic disease. The existance of the 
LDSO value in normal animals was employed as the basis for the study 
of enhanced resistance. 
By employing modifications of several methods described by 
Jordon (1960), the prepared DNP and DNA remained essentially un-
altered. With the use of material that still retained its "chemical 
anatomy", it is believed that the intact molecules could be recog-
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nized as a specific antigenic substance which differed from normal 
cell constituents. This is consistent with Landsteiner's (1946) 
work in which it was demonstrated that simple side chains of organic 
compounds could be recognized as imparting antigenic specificity. 
The purity of DNA was established by ultraviolet absorption with a 
known standard. The purity of DNP was not assayed because of the 
insolubility of this substance; it was assumed, however, from the 
results obtained after the removal of the protein moiety from the 
DNP molecule that DNP was a relatively pure preparation. 
The results, using DNP as the immunizing agent, indicated that 
substantial protection was afforded against challenge by viable 
tumor cells. This is particularly true using DNP derived from EAT 
cells. Mice immunized with 8-37 DNP showed considerably less pro-
tection; however, the mortality figures still support the fact that 
immunity can be established using this preparation. These results 
support Zilber's (1958) findings demonstrating an antibody to DNP. 
This latter investigation demonstrated DNP antigenic capacity by 
anaphylaxis and not by any protective measure that might be elicited 
using challenge tests. Zilber's (1958) findings are in contrast to 
some reports indicating that preparations of nuclear materials exhib-
ited weak antibody response (Lackman al., 1940 and Phillips et ale 
1959). Zilber's methods of extraction were apparently less denaturing 
than previous workers. 
The fact that immunization with DNP prepared from one tumor 
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followed by challenge with tumor cells of another resulted in pro-
tection might be interpreted to mean that the original hypothesis 
tha.t cancer cells per ~ contain specific antigens is not tenable. 
However, DNP from normal tissue was not protective and the results 
obtained under the circumstances of the experimental designs described 
indicate that DNP from these two different tumors contain mutual 
antigens. 
Results of similar experiments involving DNA without its pro-
tein moiety further supports the concept that the antigenic capabili-
ties must reside in the molecular arrangement of DNA from cancer cells. 
Although demonstration of protection as tested by challenge was quan-
titatively less than when DNP was used for immunization, protection 
was still enhanced although to a lesser degree. This is consistent 
with the fact demonstrated by Landsteiner (1946), that the antigenic 
specificity resides in the molecular arrangement of simple organic 
compounds but that this capacity is demonstrable only when the simple 
compounds were first coupled to a protein carrier. 
The experiments involving DNP prepared from normal mouse tissue 
yielded significant results. That is, this material provided no 
protection as an immunizing agent. When mice immunized according 
to the standard schedule were tested by challenge with tumor cells, 
no protection was noted either measured as decreased mortality or 
increased longevity. This finding furthers the concept of the exis-
tence of tumor specific antigens. 
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There are available at present few reports concerning the 
possible role of macrophages in resistance to neoplastic disease. 
Amos (1960) reported active ingestion and digestion of E.L. 4 and 
L12l0 tumor cells by histiocytes from C3H mice in vivo as well as 
a direct antagonistic effect of histiocytes on MCLM tumor cells. 
Similarly, Weaver (1958) described the role of macrophages in 
ingestion and intracellular distruction of DBA/2 thymus tumor cells 
in ascites form in C57 BL/6 mice. Microscopic examination of the 
cellular response made by observing tumor cells and macrophages 
from peritoneal washings of normal and immunized mice substantiated 
the observations of Baker ~ al. (1962) and Linderman (1964). The 
experimental data of these latter investigators demonstrated that 
the initial defence mechanism primarily concerned macrophages. 
However, Linderman (1964) also demonstrated that serum or plasma 
from immune mice could transfer immunity to challenge by the original 
viable tumor. Our observations included not only an initial influx 
of macrophages and lymphocytes in the immune animal, but also what 
appeared to be lysis of some viable tumor cells. Thus, it was assumed 
from this limited experience that the defense mechanisms involved 
were not only cellular but also humoral. Further experimentation 
would be needed to substantiate these observations. 
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SUMMARY 
1. LD50 values and 95% confidence limits were determined for the 
ip route with one strain each of EAT and S-37 tumors. The values 
obtained were: for EAT 2,000 ~ 560; for S-37 45,000 ~ 11,866. 
2. DNP and DNA were prepared from EAT and S-37 tumors and the pre-
pared material was used for immunization. 
3. Mice immunized with DNP prepared from EAT and S-37 and subse-
quently challenged with vi~ble EAT and S-37 tumor cells showed 
a considerable degree of resistance as compared to the unimmunized 
control animals. 
4. Cross immunity was demonstrated between mice immunized with DNP 
from one tumor and challenged with tumor cells other than the 
type used for immunization. 
5. Mice immunized with DNA prepared from EAT and S-37 cells and 
challenged with viable EAT and S-37 tumor cells showed increased 
resistance as compared to the unimmunized control animals. The 
degree of resistance induced using material without the protein 
moiety was less than that induced by using DNP. 
6. Cross immunity was also demonstrated between mice immunized with 
DNA from one type of tumor cell and then challenged with tumor 
cells other than the type from which the nucleic acid for immuni-
zation was obtained. However, the immunity in this latter cir-
cumstance was considerably less than when the immunization was 
carried out with the corresponding DNP. 
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7. DNP prepared from normal mouse tissue and used for immunization 
showed no measurable induction of resistance when the mice were 
tested by challenge with viable tumor cells. 
8. Microscopic observation of peritoneal washings from immunized 
and normal mice that had been challenged with viable tumor 
cells showed a significantly different cellular and humoral 
response over a 72-hour period, This response was indicated by 
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RESEARCH PROPOSALS 
1. Studies have indicated that DNA from neoplastic cells 
contain cancer specific antigen(s)0 Would recombination of DNA 
from different types of cancerous tissue increase the antigenicity? 
2. It has been found that if solutions of DNA from Escherichia 
coli and Shigella dysenteriae were heated together and cooled slowly 
they formed some hybrid double stranded molecules with one strand 
from each type of DNA. By combining DNA from different viruses, 
can antigenicity be increased? 
3. Critical, properly designed investigation should be under-
taken to determine whether DNP prepared from cancer tissue removed 
at surgery can be used to augment resistance to the neoplastic pro-
cess in humans. 
4. Since ribosomes are the final agents in protein synthesis 
which is mediated by messenger RNA from DNA, does ribosomal RNA 
contain a cancer specific antigen? 
5. Some strains of mice develop mammary carcinoma which is 
transmitted by the "milk factor" from parent to offspring. Could 
these mice be protected from developing carcinoma by immunizing 
with DNP from these solid tumors? 
6. Since DNA appears to be antigenically specific in cancer 
tissue, would DNA from normal tissue exhibit antigenicity in allo-
genic experiments of tissue transplantation? If antigenicity could 
be thus demonstrated, probable enhancement of the transplanted tissue 
might be induced. 
2 
7. Recent experiments have indicated that tumor rejection 
is primarily cellular in nature. Undoubtedly humoral mechanisms 
are also involved 0 Do these two immunological events act indepen-
dently or are they mutually dependent upon one another? 
8. Adoptive transfer is carried out by transfer of immunolog-
ically competent cells from an immune to a non-immune individual. 
Would extraction of DNP from this cell achieve the same results? 
9. There are at present many drugs used in the treatment of 
carcinoma. Could the survival rate be increased by using mice 
immunized with DNP in conjunction with anti-cancer drugs? 
10. Karyotype analysis involves culturing lymphocytes of 
the blood; could the same results be achieved by abrading the 
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